OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2018.9227 OL-0-0-9227 Review The role of interleukin-6-STAT3 signalling in glioblastoma WestAlice J. 1 * TsuiVanessa 1 * StylliStanley S. 1 2 NguyenHong P.T. 1 MorokoffAndrew P. 1 2 KayeAndrew H. 1 2 LuworRodney B. 1 Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia Correspondence to: Dr Rodney B. Luwor, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Level 5, Clinical Sciences Building, Royal Parade Street, Parkville, VIC 3050, Australia, E-mail: rluwor@unimelb.edu.au

Contributed equally

 10 2018 27 07 2018 16 4 4095 4104 30112017 26042018 Copyright: © West et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Glioblastoma is the most common type of malignant brain tumor among adults and is currently a non-curable disease due primarily to its highly invasive phenotype, and the lack of successful current therapies. Despite surgical resection and post-surgical treatment patients ultimately develop recurrence of the tumour. Several signalling molecules have been implicated in the development, progression and aggressiveness of glioblastoma. The present study reviewed the role of interleukin (IL)-6, a cytokine known to be important in activating several pro-oncogenic signaling pathways in glioblastoma. The current study particularly focused on the contribution of IL-6 in recurrent glioblastoma, with particular focus on glioblastoma stem cells and resistance to therapy.

 IL-6 STAT3 glioblastoma therapeutics Introduction

Gliomas are histologically divided into four main grades based on World Health Organisation (WHO) criteria. Grade II astrocytomas are known as diffuse astrocytomas, while grade III are anaplastic astrocytomas (AA) and are considerably more proliferative and infiltrative than grade II gliomas (1). Yet, grade IV astrocytomas or glioblastoma, despite being histologically similar to AA, are notably more proliferative, invasive and angiogenic (2). Glioblastoma is the most common and aggressive tumour of the central nervous system, and it represents 17% of all primary intracranial tumours (3). The current standard of treatment for patients with glioblastoma is maximal surgical resection, concurrent and adjuvant temozolomide and radiotherapy (known as the Stupp protocol) (4). Despite this standard of care treatment, the median survival is less than 15 months, median progression-free survival is less than 7 months and 5-year survival rate of treated patients is about 10–20% (4,5).

The tumour microenvironment plays numerous key roles in cancer progression including the release of cytokines and other effectors that mediate responses and events that aid in tumour growth (6,7). These cytokines promote factors that are central to cancer formation and progression, incorporating sustained growth, cell migration, inhibition of apoptosis and differentiation of tumour cells. It is well established that the IL-6-STAT3 signalling pathway, along with other inflammatory cytokines such as IL1β, IL-23 and TNFα has been implicated in cancer progression in many tumour types including glioblastoma contributing to tumour resistance and recurrence of glioblastoma (8).

 Interleukin-6 signalling in glioblastoma <sec> <title>Interleukin-6 (IL-6)

The ligand IL-6 is a pleiotropic cytokine of about 25 kDa (9). It was first discovered as a B cell differentiation factor (BSF-2), which induces maturation of B cells, but has since been identified as having an important role in inflammation-linked cancers, including prostate, breast, gastric, colon, lung and brain (10). IL-6 is often expressed when there are stimuli that are associated with tissue damage or stress, such as UV, viruses and the expression of other pro-inflammatory cytokines (11–13). It can be overexpressed during inflammation as an acute-phase response (14). During this inflammatory response, tumour necrosis factor alpha (TNFα) induces the expression of IL-6 (15). IL-6 subsequently regulates the inflammatory response by decreasing the expression of other pro-inflammatory cytokines along with up-regulating anti-inflammatory cytokines, such as IL-1 (15,16). IL-6 has also been shown to inhibit TNFa expression (17), demonstrating its pleiotropic nature.

IL-6 is part of the IL-6 cytokine family, which consist of IL-11, IL-27, leukaemia inhibitor factor (LIF) and oncostatin M (OSM) (18). They share the common co-receptor (gp130 β subunit), which is expressed in almost every tissue and organ in the body. It is this subunit that is responsible for the transmission of signalling into the cell by activating associated cytoplasmic tyrosine kinases (e.g. JAK), resulting in the phosphorylation of various transcription factors including STAT3 (18,19). Among the family of IL-6 cytokines, attention has focussed on IL-6 itself, as its expression levels is highly up-regulated and has been shown to be correlated with poor survival in many cancers.

 IL-6 triggered JAK-STAT3 signaling in glioblastoma

IL-6 binds and signals through its own distinct receptor alpha subunit (IL-6Rα; 80 kDa) on the plasma membrane (20). This IL-6/IL-6Rα complex then associates with the shared IL-6 family co-receptor gp130, resulting in an activated hexameric complex (two molecules of IL-6, two molecules of IL-6Ra and two molecules of gp130). There are two types of IL-6 mediated signalling: Classical and trans-signalling. Classical IL-6 signalling is the major form of IL-6 signalling and the membrane-bound IL-6R (mIL-6Rα) which is only expressed in certain tissues such as hepatocytes, some epithelial cells and leukocytes (21). Alternatively, the trans-signalling mechanism allows IL-6 signalling to occur in more cell types, as gp130 is expressed ubiquitously. This occurs due to trans-signalling of soluble IL-6Rα (sIL-6Rα), which lacks the trans-membrane domain, through the interaction with gp130. sIL-6Rα is then generated by the alternative splicing of the IL-6Rα mRNA by cytoplasm-bound metalloproteinases (ADAM10 and ADAM17) (18,22–24). As a result, the presence of sIL-6Rα permits IL-6 signalling to occur in adjacent cells. Both signalling pathways lead to the activation of JAK proteins, which are responsible for intracellular signalling and the subsequent phosphorylation of STAT transcription factors, in particular STAT3 (25).

Several studies demonstrate a correlation with IL-6 expression with glioma tumour grade and overall patient survival. IL-6 mRNA expression was found to be significantly greater in glioblastoma patient samples compared to those with lower histopathological grade (including Grade II and III astrocytomas and Grade I pilocytic astrocytomas; Table I) (26). In addition, no IL-6 gene amplification was detected in low-grade or anaplastic tumors (0/17), whereas amplification was found in 15 out of 36 (42%) glioblastoma sections (27). Importantly, this IL-6 gene amplification correlated with significantly shorter survival compared to glioblastoma patients without amplification (27). In addition, immunohistochemistry analysis identified the IL-6 receptor expression in 6/6 (100%) patient glioblastoma samples compared to 0/7 (0%) in normal brain tissue (28). IL-6 has also been detected in the cerebrospinal fluid of 11/13 (85%) and the tumor cyst fluid of 5/5 (100%) glioblastoma patients (29). In contrast, only 3/16 (19%) cerebrospinal Fluid (CSF) samples obtained from control patients had detectable IL-6 levels (29).

Once IL-6 has bound, the β subunit (gp130) homodimerises and the receptor-associated Janus Kinase (JAK1, JAK2 and Tyk2) become activated (18). Activated JAKs act as a platform for phosphorylation of STAT3. Two STAT3 monomers can form a dimer and up-regulate STAT3 target genes in the nucleus (Fig. 1). The STAT protein family is a group of transcription factors that play crucial roles in the transmission of extracellular signals into the nucleus for the transcription of a variety of genes (30,31). In cancer research, there is particular focus on STAT3 because of its oncogenic abilities. STAT3 up-regulates genes that can facilitate tumour survival, angiogenesis, resistance to cell death and cell cycle progression. Target genes of STAT3 include vascular endothelial growth factor (VEGF), Bcl-2, Bcl-xL, cyclin D1, human telomerase reverse transcriptase and c-myc (30).

Involvement of STAT3 in tumourigenesis was first described in fibroblasts and epithelial cells that were transformed by Src tyrosine kinase, where constitutive STAT3 activity was first observed (32,33). This was further supported in transgenic mice (transformed with v-src), where they developed astrocytoma that led to secondary glioblastoma (34). It only became clear that STAT3 itself could be implicated in cancer when it was found that dominant-negative STAT3 decreased tumourigenesis behaviour of src-transformed cells, whereas constitutively active STAT3 enhanced tumourigenesis (32,35,36). Interestingly, mutations within the STAT3 gene are rare, indicating that constitutive activation of STAT3 is usually due to abnormal signalling from upstream regulators, such as IL-6 (33).

STAT3 is activated in a high percentage of glioblastoma (37–39). It contributes to tumourigenesis in glioblastoma by inhibiting apoptosis, which has been demonstrated by the use of RNAi knockdowns and STAT3 inhibitors (39,40). It has also been observed that recurrent glioblastoma tumours exhibit increased phosphorylated STAT3 levels when compared with primary glioblastoma (41). Moreover, tumors which exhibited greater nuclear localization of STAT3 correlated with lower rates of recurrence-free survival and overall patient survival.

Interestingly, another study reported that the down-modulation of pSTAT3-Y705 resulted in resistance to Temozolomide, as it was able to minimise O6-methylguanine DNA methyltransferase (MGMT) expression post-transcriptionally in recurrent glioblastoma (41). It was observed in this study that STAT3 inhibition reduced MGMT levels, which led to the re-sensitisation to Temozolomide treatment (41). Potential therapies utilising STAT3 as a target are currently being investigated and clinical trials are underway for pSTAT3-Y705 inhibitors (42).

 IL-6 signalling in glioma development and cell invasion and migration

It is well established that IL-6 signalling plays a crucial role in a variety of cancers, whereby expression levels of IL-6 mRNA and protein are significantly increased in colorectal (43), prostate (44), breast (45), ovarian (46), pancreatic (46,47), lung (48) and cervical cancer (49). Weissenberger and colleagues showed the importance of IL-6 signalling in glioma and its impact on the tumorigenicity in glioblastoma, using transgenic mice (50). Mice expressing the GFAP-v-src+/− transgene develop spontaneous astrocytomas with a penetrance of around 21% (12 out of 56). However, only 1 out of 35 transgenic mice (3%) that lack IL-6 developed astrocytic tumour formation (50).

IL-6 signalling promotes a variety of activities that support gliomagenesis including cell invasion and migration, contributing to the invasive nature of glioblastoma, resulting in reduced treatment efficacy and high rates of recurrence. STAT3 activation induced by IL-6 signalling has been shown to promote cell invasion and migration in U251 and T98G glioblastoma cells (51). In a study by Liu et al (51), increased levels of IL-6 positively correlated with the levels of matrix metalloproteinase-9 (MMP-9) expression. MMPs belong to a family of proteases responsible for degrading extracellular matrix proteins and play a major role in migration (both adhesion and dispersion) as well as cell proliferation. Similarly, a study by Li et al (52), demonstrated IL-6 stimulation of U87MG glioblastoma cells resulted in increased MMP-2 expression and secretion and enhanced cell invasion.

Furthermore, IL-6 signalling correlates with increased fascin-1 expression. Fascin-1 is involved in cell invasion by the formation of actin-based protrusions known as invadopodia and the subsequent degradation of the extracellular matrix to promote migration and invasion (52). Immunofluorescence staining of fascin-1 revealed that the number of protrusions increased and fascin-1 protein was localised to the peripheries of the cell when glioblastoma cells were treated with IL-6. This study demonstrated that IL-6 signalling influences the distribution of fascin-1 and alters the structural aspects of the cell to become a more invasive phenotype in glioblastoma cells (51).

 IL-6 signalling and tumour angiogenesis

Tumour angiogenesis is another crucial process that is required for the growth and invasion of tumours. Angiogenesis requires migration of vascular endothelial cells into the tumour bulk (51). This process involves the release of mediators such as TNF-β, TNF-α, MMP-9, MMP-2 and VEGF (53). The STAT3 transcription factor is known to up-regulates the expression of VEGF-2 and its receptor, VEGFR-2, contributing to invasion through the action of IL-6 signalling and subsequent JAK-STAT3 activation (54–56). IL-6 secretion into neighbouring cells further induces this behaviour, thereby promoting cell migration through these vascular endothelial cells (51).

VEGF is an important mediator in tumour-induced angiogenesis. It has been observed that high expression of VEGF correlates with higher tumour grade and shorter survival (57,58), while one of the mechanisms of progression in glioblastoma is postulated to involve tumour resistance to anti-angiogenic treatments (59,60). This may be due to these angiogenic switches and up-regulation of different angiogenic pathways (57,61–63) as well as mesenchymal cell transition (64).

Another essential pro-angiogenic factor is fibroblastic growth factor-2 (FGF-2), which is a heparin-binding protein that has a range of roles, including serving an important pathway in tumorigenesis (65). Recent research has indicated that both VEGF and FGF2 work together to influence the process of angiogenesis. It has been shown that when both factors are expressed in mouse models, there is enhanced tumour growth coupled with the presence of high density vessels. When either FGF2 or VEGF signalling is inhibited, the rate of the tumour growth decreases significantly (65–67). Although an early study (20) showed that IL-6 acts as a growth factor in glioblastoma, a more recent study did not reach this conclusion and demonstrated that IL-6 did not have a proliferative effect in GBM cell lines, but instead promoted a more invasive phenotype by increasing the migration ability of cells (51).

 IL-6 signalling promotes resistance to cell death

In addition to evading growth suppression signaling through the loss of TP53 function, tumours such as glioblastoma are also associated with an increase in the expression of anti-apoptotic regulators or down-regulation of pro-apoptotic factors. IL-6 signalling disrupts the balance between anti- and pro-apoptotic protein expression by favouring anti-apoptotic signalling through JAK-STAT3 activation, as well as NF-kB signalling, which activates the expression of many anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1 (51,68). These anti-apoptotic proteins are also important in cell proliferation as they are direct targets of STAT3 (69). Other than increased Bcl-2 and Bcl-xL expression, IL-6 also promotes the expression of survivin through JAK-STAT3 activation (69,70). It has been found that the downregulation of survivin by inhibiting STAT3 induces apoptosis in tumour cells (70).

 Glioblastoma stem cells

Cancer stem cells (CSCs) are a group of tumour cells that have stem cell-like properties and are capable of self-renewal. Studies have shown that CSCs are critical in the progression of cancer and resistance to various therapies in different types of solid tumours, including brain tumours (71–76). In recent years the cancer stem cell (CSC) hypothesis has grown in popularity. This states that a small group of cells can maintain the cancer growth and survival, whilst providing resistance to therapy. It has been established that gliomas are one of the tumours where cancer stem cells, or glioma stem cells (GSCs) has been established (77,78). Subsequently, GSCs have been intensely studied for understanding their capacity for self-renewal and importantly, their contribution to therapeutic resistance as well as tumour recurrence (79). GSCs are thought to play important roles in gliomagenesis, recurrence and aggressiveness (80,81).

In other cancers, IL-6 is also implicated in promoting STAT3 mediated CSC expansion, such as in prostate and breast CSCs (82–84). Through the activation of JAK-STAT3 signalling (mainly from IL-6 signalling), hypoxic conditions activate these CSCs and promote self-renewal (85). It was found that upon STAT3 inhibition, GSCs lose their stem-cell phenotype permanently, suggesting that STAT3 is required for the self-renewal and growth of stem cells within glioblastoma (40,86). The contribution of CSCs to the difficulty of cancer treatment and therapy is crucial, and targeting the JAK-STAT3 pathway may therefore become a potential mechanism to overcome CSC-mediated Temozolomide resistance in glioblastoma and other solid tumours.

Several studies have found that GSCs express the IL-6 receptor and ligand, which indicates that IL-6 could be a potential cytokine to contribute to the tumourigenicity of these GSCs. Wang et al (2009) (87) found that GSCs co-expressed elevated levels of IL-6Rα and gp130 (β subunit), as demonstrated by immunofluorescence staining, although they also showed that IL-6 mRNA levels were lower in GSCs that non-GSCs. Knockdown of IL-6 or IL-6Rα by shRNA led to reduced cell growth, neurosphere formation and increased cell death in GSCs isolated from D456MG human glioma xenografts. IL-6 or IL-6Rα suppression also led to reduced tumour growth and increased survival of mice bearing intracranial xenografts (87). IL-6 has also been shown to induces the expression of glioma pathogenesis-related 1 (GPR1, also known as RTVP1) via the STAT3 pathway (88). GPR1 plays an important role in GSCs, contributing to migration, resistance to therapy and tumour recurrence. GPR1 was originally discovered in glioblastoma as one of the target genes of the tumour suppressor gene p53, one of the most commonly mutated genes in human cancer.

STAT3 has been shown to be highly expressed in GSCs, and inhibition of STAT3 levels has led to decreases in the proliferation of these GSCs (40). Furthermore, inhibition of STAT3 also diminishes the multipotency characteristic of these GSCs. STAT3 has been identified as a potential target for CSC-mediated therapy as it is the convergence point for many signaling pathways. It has been found that inhibition of STAT3 using a shRNA approach prevented proliferation and formation of neurospheres in GSCs (30,40,89). Moreover, leukaemia inhibitory factor (LIF), a member of the IL-6 family, has been found to be responsible for the tumour development of GSCs via the JAK-STAT pathway (90).

 Therapeutic targets in recurrent glioblastoma

The importance of targeting the STAT3 signalling pathway due to its function in recurrence, GSCs and resistance to Temozolomide is well established (90). Therapeutic targets of STAT3 have been investigated, but only a small number has been tested against glioblastoma (summarised in Table II). Furthermore, there has not been much success at preventing downstream nuclear signalling (91). Studies into STAT3 inhibitors should continue, as the importance of this pathway is continually being demonstrated (92,93). Furthermore, the inhibitors that have been investigated with glioblastoma generally have had significant challenges in the translation into clinical practice, mainly because of the form of administration, toxicity, cell permeability and non-selective activity (91).

The disruption of upstream receptor tyrosine kinases is one of the potential methods for inhibiting STAT3 activity. By inhibiting JAKs, growth factor receptors, receptor tyrosine kinases (RTKS) and cytokine receptors, it would be possible to alter downstream STAT3 activity. However, STAT3 is the convergence point of several oncogenic signalling pathways, including EGFR, heregulin-2/neuregulin receptor (Her2/Neu), Platelet Derived Growth factor receptor, IL-6R/gp130, c-Met, Abelson Leukemia protein (Abl), and Src tyrosine kinases. Therefore, it would be probable that a compensatory pathway could override the initial inhibition of STAT3 (94–98). On the other hand, preventing homodimersation of STAT3 involves blocking the SH2 domains from coming together after STAT3 phosphorylation, and ultimately inhibiting STAT3′s transcription capabilities. Thus far, studies have targeted the SH2 domain to prevent homodimerisation (99–102). Two groups (100,101) have shown that blocking the phosphorylated tyrosine peptide at position 705 was able to prevent STAT3 from binding to DNA in the nucleus and furthermore, the SH2 domain of STAT3 has been shown to interact with upstream signalling proteins to STAT3, including EGFR and IL-6 and its receptor. Studies that have targeted this particular homodimerisation have generated positive results, yet they have yet to be translated into an in vivo setting (28,103–105).

 Mechanism of STAT3 action in recurrent glioblastoma <sec> <title>JAK/STAT activation

There is a lack of evidence regarding the mechanism of action of over-activation of STAT3 in recurrent glioblastoma. The STAT3 signalling pathway has been extensively investigated in primary glioblastoma, but it has not yet been shown why phosphorylated STAT3 is overexpressed in recurrent glioblastoma compared to primary glioblastoma (44). Furthermore, increased phosphorylation of STAT3 has been correlated with increased grade of astrocytoma (106,107). Based on this evidence, it is possible that STAT3 could be considered as a prognostic factor. Tu et al (107), have demonstrated that JAK/STAT activation is correlated to higher grade gliomas, and furthermore, it was shown that JAK/STAT activation is a prognostic indicator of decreased survival. One potential mode of action is through a mutated MSH6 gene, which has been correlated with a methylated O6-methylguanine-DNA transferase (MGMT) promoter, whose cellular levels are known to be regulated by STAT3 through IL-6 (41). This potential mechanism is outlined in the next section.

 IL-6-STAT3 signaling and MGMT

Currently, the DNA repair protein, MGMT, is the most studied predictive biomarker of response to temozolomide treatment in patients with glioblastoma. Temozolomide exerts its cytotoxic activity by methylating specific DNA sites including the O6 position of the nucleotide guanine, resulting in cell death (108). MGMT directly inhibits the cytotoxic effect of temozolomide by removing the methyl group off the O6 position of guanine in DNA (109,110). Thus, patients with glioblastoma that expressed reduced MGMT due to epigenetic methylation of the MGMT promoter have better response rates to temozolomide and are associated with longer overall survival (Fig. 2) (111).

A study by Piperi et al (112) identified methylation of MGMT in 58.8% of tissue surgically resected from 23 glioblastoma patients. Patients with tumour tissue containing MGMT methylation had a poorer overall median survival of 12 months compared to patients with tissue absent of MGMT methylation (16 months). Importantly, MGMT methylation in this study was found to also correlate with IL-6 expression (112). Despite this paper not examining STAT3 activity, one can speculate that enhanced STAT3 activation (through increased IL-6 expression) may mediate temozolomide sensitivity and poorer overall outcomes.

In support of this notion is the study from Koksaka and colleagues who did indeed evaluate a potential correlation between phosphorylated STAT3 and MGMT expression (41). In this paper, a significant correlation was observed between pSTAT3 staining intensity by immunohistochemistry with MGMT expression in 44 surgically resected human glioma specimens. Koksaka and colleagues also generated a U87MG sub-population that was temozolomide-refractory after 3 weeks of continuous exposure to low-dose temozolomide. These resistant cells designated U87R displayed greater expression of IL-6, STAT3 and MGMT compared to their sensitive parental counterparts. Importantly, pharmacological inhibition of STAT3 or STAT3 knockdown with shRNA resulted in reduced MGMT expression in the U87R cells and other glioblastoma cell lines. STAT3 inhibition also re-sensitized cells to temozolomide (41).

Taken together, these articles strongly link IL-6-STAT3 signaling with MGMT expression and methylation and to temozolomide sensitivity. However, further studies are required to investigate the mechanisms of action for the epigenetic control of tumour cell functions by IL-6. Overall, it would be advantageous to extensively study the potential of IL-6/STAT3 inhibitors on MGMT expression levels, and determine if this could potentially aid in overcoming temozolomide resistance in glioblastoma considering that MGMT requires STAT3 activation to modulate cellular levels of MGMT.

 Conclusions

Understanding how overexpressed or over-active signalling pathways promote recurrent glioblastoma progression may lead to the development of new therapies. In particular, targeting the important IL-6-JAK/STAT3 signaling pathway should result in reduced tumour proliferation and invasion and improved patient outcomes. In addition, therapeutic targeting of STAT3 and its components may provide a basis for sensitising these recurrent tumours to the currently available treatments for glioma. For this strategy to proceed, further preclinical research into how IL-6-STAT3 promotes glioblastoma recurrence and progression is still required.

 Acknowledgements

Not applicable.

 Funding

RBL is a mid-career fellowship holder with the Victorian Cancer Agency (grant no. MCRF 15017).

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

AJW, VT and RBL contributed to the writing of this manuscript, while HPTN, SSS, APM, AHK and RBL contributed the conception design and editing of the manuscript.

 Ethics approval and consent to participate

Not applicable.

 Consent for publication

Not applicable.

 Competing interests

The authors declare that there are no competing interests.

 References AldapeKZadehGMansouriSReifenbergerGvon DeimlingAGlioblastoma: Pathology, molecular mechanisms and markersActa Neuropathol129829848201510.1007/s00401-015-1432-125943888 AgnihotriSBurrellKEWolfAJalaliSHawkinsCRutkaJTZadehGGlioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategiesArch Immunol Ther Exp (Warsz)612541201310.1007/s00005-012-0203-023224339 WenPYKesariSMalignant gliomas in adultsN Engl J Med359492507200810.1056/NEJMra070812618669428 StuppRMasonWPvan den BentMJWellerMFisherBTaphoornMJBelangerKBrandesAAMarosiCBogdahnURadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med352987996200510.1056/NEJMoa04333015758009 TullyPAGogosAJLoveCLiewDDrummondKJMorokoffAPReoperation for recurrent glioblastoma and its association with survival benefitNeurosurgery79678689201610.1227/NEU.000000000000133827409404 DesbailletsIDiserensACTriboletNHamouMFVan MeirEGUpregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesisJ Exp Med18612011212199710.1084/jem.186.8.12019334359 ShanYHeXSongWHanDNiuJWangJRole of IL-6 in the invasiveness and prognosis of gliomaInt J Clin Exp Med891149120201526309566 JarnickiAPutoczkiTErnstMStat3: Linking inflammation to epithelial cancer-more than a ‘gut’ feeling?Cell Div514201010.1186/1747-1028-5-1420478049 KumariNDwarakanathBSDasABhattANRole of interleukin-6 in cancer progression and therapeutic resistanceTumour Biol371155311572201610.1007/s13277-016-5098-727260630 IliopoulosDHirschHAStruhlKAn epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformationCell139693706200910.1016/j.cell.2009.10.01419878981 AkiraSKishimotoTIL-6 and NF-IL6 in acute-phase response and viral infectionImmunol Rev1272550199210.1111/j.1600-065X.1992.tb01407.x1380488 WuCTChenMFChenWCHsiehCCThe role of IL-6 in the radiation response of prostate cancerRadiat Oncol8159201310.1186/1748-717X-8-15923806095 YangRLinQGaoHBZhangPStress-related hormone norepinephrine induces interleukin-6 expression in GES-1 cellsBraz J Med Biol Res47101109201410.1590/1414-431X2013334624519125 SchellerJChalarisASchmidt-ArrasDRose-JohnSThe pro- and anti-inflammatory properties of the cytokine interleukin-6Biochim Biophys Acta1813878888201110.1016/j.bbamcr.2011.01.03421296109 GruysEToussaintMJNiewoldTAKoopmansSJAcute phase reaction and acute phase proteinsJ Zhejiang Univ Sci B610451056200510.1631/jzus.2005.B104516252337 TilgHTrehuEAtkinsMBDinarelloCAMierJWInterleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55Blood8311311819948274730 AderkaDLeJMVilcekJIL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in miceJ Immunol1433517352319892584704 JonesSASchellerJRose-JohnSTherapeutic strategies for the clinical blockade of IL-6/gp130 signalingJ Clin Invest12133753383201110.1172/JCI5715821881215 MiharaMHashizumeMYoshidaHSuzukiMShiinaMIL-6/IL-6 receptor system and its role in physiological and pathological conditionsClin Sci (Lond)122143159201210.1042/CS2011034022029668 GoswamiSGuptaASharmaSKInterleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MGJ Neurochem7118371845199810.1046/j.1471-4159.1998.71051837.x9798907 TagaTKishimotoTGp130 and the interleukin-6 family of cytokinesAnnu Rev Immunol15797819199710.1146/annurev.immunol.15.1.7979143707 ChalarisAGarbersCRabeBRose-JohnSSchellerJThe soluble interleukin 6 receptor: Generation and role in inflammation and cancerEur J Cell Biol90484494201110.1016/j.ejcb.2010.10.00721145125 JonesSAHoriuchiSTopleyNYamamotoNFullerGMThe soluble interleukin 6 receptor: Mechanisms of production and implications in diseaseFASEB J154358200110.1096/fj.99-1003rev11149892 YoshidaKTagaTSaitoMSuematsuSKumanogohATanakaTFujiwaraHHirataMYamagamiTNakahataTTargeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disordersProc Natl Acad Sci USA93407411199610.1073/pnas.93.1.4078552649 YeungYTMcDonaldKLGrewalTMunozLInterleukins in glioblastoma pathophysiology: Implications for therapyBr J Pharmacol168591606201310.1111/bph.1200823062197 RolhionCPenault-LlorcaFKéményJLLemaireJJJullienCLabit-BouvierCFinat-DuclosFVerrellePInterleukin-6 overexpression as a marker of malignancy in human gliomasJ Neurosurg9497101200110.3171/jns.2001.94.1.009711147905 TchirkovAKhalilTChautardEMokhtariKVéronèseLIrthumBVagoPKéményJLVerrellePInterleukin-6 gene amplification and shortened survival in glioblastoma patientsBr J Cancer96474476200710.1038/sj.bjc.660358617224923 KudoMJonoHShinrikiSYanoSNakamuraHMakinoKHideTMutaDUedaMOtaKAntitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigationJ Neurosurg111219225200910.3171/2008.12.JNS08128419326989 Van MeirESawamuraYDiserensACHamouMFde TriboletNHuman glioblastoma cells release interleukin 6 in vivo and in vitroCancer Res506683668819902208133 AshizawaTMiyataHIizukaAKomiyamaMOshitaCKumeANogamiMYagotoMItoIOishiTEffect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastomaInt J Oncol43219227201310.3892/ijo.2013.191623612755 ZhongZWenZDarnellJEJrStat3 and Stat4: Members of the family of signal transducers and activators of transcriptionProc Natl Acad Sci USA9148064810199410.1073/pnas.91.11.48067545930 BrombergJFHorvathCMBesserDLathemWWDarnellJEJrStat3 activation is required for cellular transformation by v-srcMol Cell Biol1825532558199810.1128/MCB.18.5.25539566875 OuédraogoZGBiauJKemenyJLMorelLVerrellePChautardERole of STAT3 in genesis and progression of human malignant gliomasMol Neurobiol5457805797201710.1007/s12035-016-0103-027660268 SmilowitzHMWeissenbergerJWeisJBrownJDO'NeillRJLaissueJAOrthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: Establishment of a new transplantable in vivo model for malignant gliomaJ Neurosurg106652659200710.3171/jns.2007.106.4.65217432718 DechowTNPedranziniLLeitchALeslieKGeraldWLLinkovIBrombergJFRequirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-CProc Natl Acad Sci USA1011060210607200410.1073/pnas.040410010115249664 TurksonJBowmanTGarciaRCaldenhovenEDe GrootRPJoveRStat3 activation by Src induces specific gene regulation and is required for cell transformationMol Cell Biol1825452552199810.1128/MCB.18.5.25459566874 Catlett-FalconeRLandowskiTHOshiroMMTurksonJLevitzkiASavinoRCilibertoGMoscinskiLFernández-LunaJLNuñezGConstitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cellsImmunity10105115199910.1016/S1074-7613(00)80011-410023775 GrandisJRDrenningSDChakrabortyAZhouMYZengQPittASTweardyDJRequirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitroJ Clin Invest10213851392199810.1172/JCI37859769331 RahamanSOHarborPCChernovaOBarnettGHVogelbaumMAHaqueSJInhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cellsOncogene2184048413200210.1038/sj.onc.120604712466961 SherryMMReevesAWuJKCochranBHSTAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cellsStem Cells2723832392200910.1002/stem.18519658181 KohsakaSWangLYachiKMahabirRNaritaTItohTTaninoMKimuraTNishiharaHTanakaSSTAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expressionMol Cancer Ther1112891299201210.1158/1535-7163.MCT-11-080122532597 HeimbergerABThe therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignanciesSurg Neurol Int2163201110.4103/2152-7806.8988622140648 WaldnerMJFoerschSNeurathMFInterleukin-6-a key regulator of colorectal cancer developmentInt J Biol Sci812481253201210.7150/ijbs.461423136553 CuligZPuhrMInterleukin-6: A multifunctional targetable cytokine in human prostate cancerMol Cell Endocrinol3605258201210.1016/j.mce.2011.05.03321664423 DethlefsenCHøjfeldtGHojmanPThe role of intratumoral and systemic IL-6 in breast cancerBreast Cancer Res Treat138657664201310.1007/s10549-013-2488-z23532539 MacciòAMadedduCThe role of interleukin-6 in the evolution of ovarian cancer: Clinical and prognostic implications-a reviewJ Mol Med (Berl)9113551368201310.1007/s00109-013-1080-724057813 MiuraTMitsunagaSIkedaMShimizuSOhnoITakahashiHFuruseJInagakiMHigashiSKatoHCharacterization of patients with advanced pancreatic cancer and high serum interleukin-6 levelsPancreas44756763201510.1097/MPA.000000000000033525931255 ChangCHHsiaoCFYehYMChangGCTsaiYHChenYMHuangMSChenHLLiYJYangPCCirculating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapyInt J Cancer13219771985201310.1002/ijc.2789223034889 WeiLHKuoMLChenCAChouCHLaiKBLeeCNHsiehCYInterleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathwayOncogene2215171527200310.1038/sj.onc.120622612629515 WeissenbergerJLoefflerSKappelerAKopfMLukesAAfanasievaTAAguzziAWeisJIL-6 is required for glioma development in a mouse modelOncogene2333083316200410.1038/sj.onc.120745515064729 LiuQLiGLiRShenJHeQDengLZhangCZhangJIL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell linesJ Neurooncol100165176201010.1007/s11060-010-0158-020361349 LiRLiGDengLLiuQDaiJShenJZhangJIL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1Oncol Rep2315531559201010.3892/or_0000079520428809 AntonKBanerjeeDGlodJMacrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretionPLoS One7e35036201210.1371/journal.pone.003503622496888 CarmelietPAngiogenesis in life, disease and medicineNature438932936200510.1038/nature0447816355210 GaronnaEBothamKMBirdseyGMRandiAMGonzalez-PerezRRWheeler-JonesCPVascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cellsPLoS One6e18823201110.1371/journal.pone.001882321533119 ShibuyaMVascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseasesJ Biochem1531319201310.1093/jb/mvs13623172303 LabussièreMCheneauCPrahstCGállego Pérez-LarrayaJFarinaPLombardiGMokhtariKRahimianADelattreJYEichmannASansonMAngiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastomaCancer Invest343944201610.3109/07357907.2015.108894826735326 ZhouYHTanFHessKRYungWKThe expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survivalClin Cancer Res933693375200312960124 BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer8592603200810.1038/nrc244218650835 TakanoSGlioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formationBrain Tumor Pathol297386201210.1007/s10014-011-0077-622218709 LiJLSainsonRCOonCETurleyHLeekRSheldonHBridgesEShiWSnellCBowdenETDLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivoCancer Res7160736083201110.1158/0008-5472.CAN-11-170421803743 PetersonTEKirkpatrickNDHuangYFarrarCTMarijtKAKloepperJDattaMAmoozgarZSeanoGJungKDual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophagesProc Natl Acad Sci USA11344704475201610.1073/pnas.152534911327044097 TabouretEDenicolaiEDelfinoCGraillonTBoucardCNanniIPadovaniLFigarella-BrangerDChinotOChanges in PlGF and MET-HGF expressions in paired initial and recurrent glioblastomaJ Neurooncol130431437201610.1007/s11060-016-2251-527566180 PiaoYLiangJHolmesLHenryVSulmanEde GrootJFAcquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transitionClin Cancer Res1943924403201310.1158/1078-0432.CCR-12-155723804423 WescheJHaglundKHaugstenEMFibroblast growth factors and their receptors in cancerBiochem J437199213201110.1042/BJ2010160321711248 FuZChenXGuanSYanYLinHHuaZCCurcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathwayOncotarget61946919482201510.18632/oncotarget.362526254223 WuXYXuHWuZFChenCLiuJYWuGNYaoXQLiuFKLiGShenLFormononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical modelsOncotarget64456344578201510.18632/oncotarget.631026575424 WaxmanABKolliputiNIL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusinsAm J Respir Cell Mol Biol41385396200910.1165/rcmb.2008-0302OC19168699 HiranoTIshiharaKHibiMRoles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptorsOncogene1925482556200010.1038/sj.onc.120355110851053 GritskoTWilliamsATurksonJKanekoSBowmanTHuangMNamSEweisIDiazNSullivanDPersistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cellsClin Cancer Res121119200610.1158/1078-0432.CCR-04-175216397018 BonnetDDickJEHuman acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNat Med3730737199710.1038/nm0797-7309212098 ClarkeMFFullerMStem cells and cancer: Two faces of eveCell12411111115200610.1016/j.cell.2006.03.01116564000 LapidotTSirardCVormoorJMurdochBHoangTCaceres-CortesJMindenMPatersonBCaligiuriMADickJEA cell initiating human acute myeloid leukaemia after transplantation into SCID miceNature367645648199410.1038/367645a07509044 MageeJAPiskounovaEMorrisonSJCancer stem cells: Impact, heterogeneity, and uncertaintyCancer Cell21283296201210.1016/j.ccr.2012.03.00322439924 VisvaderJELindemanGJCancer stem cells in solid tumours: Accumulating evidence and unresolved questionsNat Rev Cancer8755768200810.1038/nrc249918784658 WillyardCStem cells: Bad seedsNature498S12S13201310.1038/498S12a23803943 GalliRBindaEOrfanelliUCipellettiBGrittiADe VitisSFioccoRForoniCDimecoFVescoviAIsolation and characterization of tumorigenic, stem-like neural precursors from human glioblastomaCancer Res6470117021200410.1158/0008-5472.CAN-04-136415466194 SinghSKClarkeIDTerasakiMBonnVEHawkinsCSquireJDirksPBIdentification of a cancer stem cell in human brain tumorsCancer Res6358215828200314522905 HossainAGuminJGaoFFigueroaJShinojimaNTakezakiTPriebeWVillarrealDKangSGJoyceCMesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathwayStem Cells3324002415201510.1002/stem.205325966666 JafriNFClarkeJLWeinbergVBaraniIJChaSRelationship of glioblastoma multiforme to the subventricular zone is associated with survivalNeuro Oncol159196201310.1093/neuonc/nos26823095230 YoungGSMacklinEASetayeshKLawsonJDWenPYNordenADDrappatzJKesariSLongitudinal MRI evidence for decreased survival among periventricular glioblastomaJ Neurooncol104261269201110.1007/s11060-010-0477-121132516 KroonPBerryPAStowerMJRodriguesGMannVMSimmsMBhasinDChettiarSLiCLiPKJAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cellsCancer Res7352885298201310.1158/0008-5472.CAN-13-087423824741 MarottaLLAlmendroVMarusykAShipitsinMSchemmeJWalkerSRBloushtain-QimronNKimJJChoudhurySAMaruyamaRThe JAK2/STAT3 signaling pathway is required for growth of CD44+CD24stem cell-like breast cancer cells in human tumorsJ Clin Invest12127232735201110.1172/JCI4474521633165 SchroederAHerrmannACherryholmesGKowolikCBuettnerRPalSYuHMüller-NewenGJoveRLoss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signalingCancer Res7412271237201410.1158/0008-5472.CAN-13-059424177177 ZhouBDamrauerJSBaileySTHadzicTJeongYClarkKFanCMurphyLLeeCYTroesterMAErythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewalJ Clin Invest124553563201410.1172/JCI6980424435044 GuoXQiuJTuTYangXDengLAndersRAZhouLFuYXInduction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infectionImmunity402539201410.1016/j.immuni.2013.10.02124412612 WangHLathiaJDWuQWangJLiZHeddlestonJMEylerCEElderbroomJGallagherJSchuschuJTargeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growthStem Cells2723932404200910.1002/stem.18819658188 GiladiNDZiv-AvALeeHKFinnissSCazacuSXiangCWaldman Ben-AsherHdeCarvalhoAMikkelsenTPoissonLBrodieCRTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loopOncotarget62268022697201510.18632/oncotarget.420526267319 LiGHWeiHLvSQJiHWangDLKnockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cellsInt J Oncol37103110201020514402 YuHLeeHHerrmannABuettnerRJoveRRevisiting STAT3 signalling in cancer: New and unexpected biological functionsNat Rev Cancer14736746201410.1038/nrc381825342631 JacksonCRuzevickJAminAGLimMPotential role for STAT3 inhibitors in glioblastomaNeurosurg Clin N Am23379389201210.1016/j.nec.2012.04.00222748651 ChangQBournazouESansonePBerishajMGaoSPDalyLWelsJTheilenTGranittoSZhangXThe IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasisNeoplasia15848862201310.1593/neo.1370623814496 LiangQMaCZhaoYGaoGMaJInhibition of STAT3 reduces astrocytoma cell invasion and constitutive activation of STAT3 predicts poor prognosis in human astrocytomaPLoS One8e84723201310.1371/journal.pone.008472324386409 BowmanTBroomeMASinibaldiDWhartonWPledgerWJSedivyJMIrbyRYeatmanTCourtneidgeSAJoveRStat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesisProc Natl Acad Sci USA9873197324200110.1073/pnas.13156889811404481 HodgeDRHurtEMFarrarWLThe role of IL-6 and STAT3 in inflammation and cancerEur J Cancer4125022512200510.1016/j.ejca.2005.08.01616199153 KortylewskiMYuHStat3 as a potential target for cancer immunotherapyJ Immunother30131139200710.1097/01.cji.0000211327.76266.6517471161 YuCLMeyerDJCampbellGSLarnerACCarter-SuCSchwartzJJoveREnhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoproteinScience2698183199510.1126/science.75415557541555 ZhongZWenZDarnellJEJrStat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6Science2649598199410.1126/science.81404228140422 ElliottLHBrooksWHRoszmanTLInability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptorsJ Clin Invest868086199010.1172/JCI1147192365829 FletcherSDrewryJAShahaniVMPageBDGunningPTMolecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) proteinBiochem Cell Biol87825833200910.1139/O09-04419935868 JingNTweardyDJTargeting Stat3 in cancer therapyAnticancer Drugs16601607200510.1097/00001813-200507000-0000215930886 LeemanRJLuiVWGrandisJRSTAT3 as a therapeutic target in head and neck cancerExpert Opin Biol Ther6231241200610.1517/14712598.6.3.23116503733 HeinrichPCBehrmannIMüller-NewenGSchaperFGraeveLInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathwayBiochem J334297314199810.1042/bj33402979716487 KimSRBaeMKKimJYWeeHJYooMABaeSKAspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cellsBiochem Biophys Res Commun387342347200910.1016/j.bbrc.2009.07.02219595669 ShaoHChengHYCookRGTweardyDJIdentification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptorCancer Res6339233930200312873986 Abou-GhazalMYangDSQiaoWReina-OrtizCWeiJKongLYFullerGNHiraokaNPriebeWSawayaRHeimbergerABThe incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomasClin Cancer Res1482288235200810.1158/1078-0432.CCR-08-132919088040 TuYZhongYFuJCaoYFuGTianXWangBActivation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomasMed Oncol281523201110.1007/s12032-010-9435-120135364 MinnitiGMuniRLanzettaGMarchettiPEnriciRMChemotherapy for glioblastoma: Current treatment and future perspectives for cytotoxic and targeted agentsAnticancer Res2951715184200920044633 BaerJCFreemanAANewlandsESWatsonAJRaffertyJAMargisonGPDepletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cellsBr J Cancer6712991302199310.1038/bjc.1993.2418512814 WangGWeissCShengPBresnickERetrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agentsBiochem Pharmacol5112211218199610.1016/0006-2952(96)00077-98645346 HegiMEDiserensACGorliaTHamouMFde TriboletNWellerMKrosJMHainfellnerJAMasonWMarianiLMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med3529971003200510.1056/NEJMoa04333115758010 PiperiCThemistocleousMSPapavassiliouGAFarmakiELevidouGKorkolopoulouPAdamopoulosCPapavassiliouAGHigh incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: Association with histopathological characteristics, inflammatory mediators and clinical outcomeMol Med1619201010.2119/molmed.2009.0014019809523 GiomettoBBozzaFFaresinFAlessioLMingrinoSTavolatoBImmune infiltrates and cytokines in gliomasActa Neurochir (Wien)1385056199610.1007/BF014117248686525 ChangCYLiMCLiaoSLHuangYLShenCCPanHCPrognostic and clinical implication of IL-6 expression in glioblastoma multiformeJ Clin Neurosci12930933200510.1016/j.jocn.2004.11.01716326273 SasakiAIshiuchiSKandaTHasegawaMNakazatoYAnalysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell linesBrain Tumor Pathol181321200110.1007/BF0247892011517969 HussainSFKongLYJordanJConradCMaddenTFoktIPriebeWHeimbergerABA novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patientsCancer Res6796309636200710.1158/0008-5472.CAN-07-124317942891 IwamaruASzymanskiSIwadoEAokiHYokoyamaTFoktIHessKConradCMaddenTSawayaRA novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivoOncogene2624352444200710.1038/sj.onc.121003117043651 StechishinODLuchmanHARuanYBloughMDNguyenSAKellyJJCairncrossJGWeissSOn-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cellsNeuro Oncol15198207201310.1093/neuonc/nos30223262510 McFarlandBCMaJYLangfordCPGillespieGYYuHZhengYNozellSEHuszarDBenvenisteENTherapeutic potential of AZD1480 for the treatment of human glioblastomaMol Cancer Ther1023842393201110.1158/1535-7163.MCT-11-048022027691 HeKQiQChanCBXiaoGLiuXTucker-BurdenCWangLMaoHLuXMcDonaldFEBlockade of glioma proliferation through allosteric inhibition of JAK2Sci Signal6ra55201310.1126/scisignal.200390023838182 SenftCPriesterMPolacinMSchröderKSeifertVKögelDWeissenbergerJInhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cellsJ Neurooncol101393403201110.1007/s11060-010-0273-y20589525 LoHWCaoXZhuHAli-OsmanFConstitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylatorsClin Cancer Res1460426054200810.1158/1078-0432.CCR-07-492318829483 MukthavaramROuyangXSaklechaRJiangPNomuraNPingleSCGuoFMakaleMKesariSEffect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheresJ Transl Med13269201510.1186/s12967-015-0627-526283544 FuhBSoboMCenLJosiahDHutzenBCisekKBhasinDReganNLinLChanCLLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma modelBr J Cancer100106112200910.1038/sj.bjc.660479319127268 BallSLiCLiPKLinJThe small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cellsPLoS One6e18820201110.1371/journal.pone.001882021526200 SaiKWangSBalasubramaniyanVConradCLangFFAldapeKSzymanskiSFoktIDasguptaAMaddenTInduction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathwayJ Neurooncol107487501201210.1007/s11060-011-0786-z22249692 HanTJChoBJChoiEJKimDHSongSHPaekSHKimIAInhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivoJ Neurooncol1308998201610.1007/s11060-016-2231-927510952

STAT3 activation pathway. STAT3 is activated through the interaction of cytokines and growth factors. Growth factors have intrinsic kinase activity, whereas the receptors of ligands have associated JAK that, when phosphorylated, acts as a platform for un-phosphorylated STAT3 to become activated. Phosphorylated STAT3 dimers (not shown in figure for simplicity) translocates to the nucleus where it up-regulates a variety of genes that can contribute to tumourigenesis. The STAT3 pathway is negatively regulated by a number of ways. SOCS3 inhibits the phosphorylation of JAK proteins and PIAS3 inhibits dimerisation of STAT3 monomers. Phosphorylated STAT3 dimers are not shown for simplicity.

TMZ is an alkylating agent that induces DNA methylation of guanine at the O6 position causing double-stranded DNA breaks and ultimately cell death. MGMT is a DNA-repair protein that counteracts the apoptotic effects of temozolomide by removing alkyl groups from the O6 position of guanine enhancing cell survival. Thus glioblastoma with high MGMT expression are commonly refractory to temozolomide while glioblastoma with silenced MGMT through epigenetic methylation of the MGMT promoter display greater sensitivity to temozolomide. TMZ, Temozolomide; MGMT, O6-methylguanine DNA methyltransferase.

Percentage of positive detected IL-6 in human primary brain tumor samples by histopathological grade.

Author, date Evaluation Technique Brain tumour (Grade I–III) (%) Glioblastoma (Grade IV) (%) (Refs.)
Rolhion et al, 2001 IL-6 mRNA expression RT-PCR 7/16 (44) 38/43 (88) (26)
Rolhion et al, 2001 IL-6 protein expression IHC N/A 4/5 (80) (26)
Tchirkov et al, 2007 IL-6 gene amplification FISH 0/17 (0) 15/36 (42) (27)
Giometto et al, 1996 IL-6 protein expression IHC 3/10 (30) 4/4 (100) (113)
Chang et al, 2005 IL-6 protein expression IHC N/A 5/11 (56) (114)
Sasaki et al, 2001 IL-6 mRNA expression RT-PCR 8/20 (40) 8/9 (89) (115)
Sasaki et al, 2001 IL-6 protein expression IHC N/A 4/7 (57) (115)

IL-6, interleukin-6; IHC, immunohistochemistry; RT-PCR, reverse transcription-polymerase chain reaction; N/A, not applicable; FISH, fluorescent in situ hybridization.

Therapeutic agents targeting JAK/STAT3 in the glioblastoma setting.

Author, date Drug name Target Findings (Refs.)
Ashizawa et al, 2013 STX-0119 STAT3 Reduced cell growth and induced apoptosis in vitro and reduced tumour growth in vivo (30)
Rahaman et al, 2002 WP1066 JAK2/STAT3 Reduced cell growth in vitro and in vivo (39)
Hussain et al, 2007 WP1066 JAK2/STAT3 Reduced cell growth in vitro and in vivo (116)
Iwamaru et al, 2007 WP1066 JAK2/STAT3 Reduced cell growth in vitro and in vivo (117)
Stechishin et al, 2013 WP1066 JAK2/STAT3 Reduced cell growth in vitro and in vivo (118)
McFarland et al, 2011 AZD1480 JAK1/2 Reduced cell growth and induced apoptosis in vitro, reduced tumour growth in vivo and enhanced survival of mice bearing intracranial tumours (119)
He et al, 2013 G5-7 JAK2 Reduced cell growth in vitro and in vivo (120)
Senft et al, 2011 AG490 JAK2 Reduced cell Proliferation, migration and invasion in vitro (121)
Lo et al, 2008 JSI-124 JAK2/STAT3 Reduced cell growth and induced apoptosis in vitro (122)
Mukthavaram et al, 2015 SAR317461 JAK2/STAT3 Reduced cell growth and induced apoptosis and autophagy in vitro (123)
Fuh et al, 2009 LLL3 STAT3 Reduced cell growth and induced apoptosis in vitro and enhanced survival of mice bearing intracranial tumours (124)
Ball et al, 2011 LLL12 STAT3 Reduced cell growth and migration and induced apoptosis in vitro (125)
Sai et al, 2012 WP1193 STAT3 Reduced cell growth in vitro and in vivo (126)
Han et al, 2016 Cpd188 STAT3 Reduced cell growth in vitro and in vivo (127)

JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3.